Solbec Pharmaceuticals is continuing its investigation into the behaviour of its lead cancer product, developed from elements found in weed colloquially known as ‘Devil’s Apple’.
Results so far suggest the drug, SBP002, may be applicable in palliative care.
A UWA study commissioned by Solbec has shown the drug inhibits the production of a chemical known as interlukin, which is associated with wasting and emaciation in people with advanced cancer.
Solbec managing director Stephen Carter said this could explain why a significant percentage of trial patients reported "an increased feeling of well being with reduction in pain, reduced use of narcotic pain killers and improved appetite" when treated with SBP002.
The local ASX-listed company is also aiming to confirm a possible additional benefit of the drug.
Studies have indicated SBP002 may activate the immune system when targeting and destroying specific primary tumours, to the extent that micro secondary tumours are also attacked.
This may occur even after the drug has left a patient’s system, Mr Carter said.
Solbec has IP patents for SBP002 in both the US and Europe, the largest markets for cancer treatments.
During the past year the company has also filed patents in Australia.
Solbec has more than 2,500 shareholders, with the top-20 holding 35 per cent of the company.
Chairman Michael Ruane, who holds 20 million company shares, increased his holdings this month with two on-market trades.
